LXI-15028 50mg

DRUG2 trials

Sponsors

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Conditions

Erosive Esophagitis (EE)Healthy

Phase 1

A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability.

CompletedNCT03458650

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.Healthy

Start: 2018-03-19End: 2018-05-08Updated: 2018-05-30

Phase 3

Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis

CompletedNCT03615677

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.Erosive Esophagitis (EE)

Start: 2018-10-24End: 2019-10-18Updated: 2020-04-15

Related Papers

Efficacy and safety of tegoprazan (LXI-15028) vs. esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase Ⅲ trial

Chinese Medical Journal2024-10-306 citations